-
Je něco špatně v tomto záznamu ?
SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care
M. Balik, P. Waldauf, I. Jurisinova, E. Svobodova, M. Diblickova, T. Tencer, J. Zavora, G. Smela, L. Kupidlovska, V. Adamkova, M. Fridrichova, K. Jerabkova, J. Mikes, F. Duska, L. Dusek
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147
Agentura Pro Zdravotnický Výzkum České Republiky
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- adenosinmonofosfát * analogy a deriváty terapeutické užití MeSH
- alanin * analogy a deriváty terapeutické užití MeSH
- antivirové látky * terapeutické užití MeSH
- COVID-19 * virologie mortalita MeSH
- farmakoterapie COVID-19 * MeSH
- jednotky intenzivní péče MeSH
- lidé středního věku MeSH
- lidé MeSH
- péče o pacienty v kritickém stavu MeSH
- retrospektivní studie MeSH
- SARS-CoV-2 * účinky léků izolace a purifikace fyziologie MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- virová nálož * účinky léků MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018976
- 003
- CZ-PrNML
- 005
- 20241024111205.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-024-71588-9 $2 doi
- 035 __
- $a (PubMed)39242658
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Balik, M $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic. martin.balik@vfn.cz $1 https://orcid.org/0000000318642143 $7 xx0075661
- 245 10
- $a SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care / $c M. Balik, P. Waldauf, I. Jurisinova, E. Svobodova, M. Diblickova, T. Tencer, J. Zavora, G. Smela, L. Kupidlovska, V. Adamkova, M. Fridrichova, K. Jerabkova, J. Mikes, F. Duska, L. Dusek
- 520 9_
- $a Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a adenosinmonofosfát $x analogy a deriváty $x terapeutické užití $7 D000249
- 650 12
- $a alanin $x analogy a deriváty $x terapeutické užití $7 D000409
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a virová nálož $x účinky léků $7 D019562
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a SARS-CoV-2 $x účinky léků $x izolace a purifikace $x fyziologie $7 D000086402
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a farmakoterapie COVID-19 $7 D000093485
- 650 12
- $a COVID-19 $x virologie $x mortalita $7 D000086382
- 650 12
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a péče o pacienty v kritickém stavu $7 D003422
- 650 _2
- $a jednotky intenzivní péče $7 D007362
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Waldauf, P $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Jurisinova, I $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
- 700 1_
- $a Svobodova, E $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
- 700 1_
- $a Diblickova, M $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
- 700 1_
- $a Tencer, T $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Zavora, J $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Smela, G $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Kupidlovska, L $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Adamkova, V $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Fridrichova, M $u Department of Laboratory Diagnostics, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Jerabkova, K $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Mikes, J $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Duska, F $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Dusek, L $u Faculty of Medicine, Institute of Health Information and Statistics of the Czech Republic, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 20825
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39242658 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111159 $b ABA008
- 999 __
- $a ok $b bmc $g 2201675 $s 1230949
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 1 $d 20825 $e 20240906 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- GRA __
- $a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
- LZP __
- $a Pubmed-20241015